Irini Sereti, M.D.Building 10, Room 11B-0710 Center DriveBethesda, MD 20892-1876Phone: 301-496-5533Fax: firstname.lastname@example.org
Chief, HIV Pathogenesis Unit, LIR
The primary research focus of our group is the study of immune reconstitution inflammatory syndrome (IRIS). IRIS is an aberrant immune response, frequently with an intense inflammatory component, that can occur in the context of immune restoration in patients with HIV infection and severe CD4 lymphopenia after initiation of antiretroviral therapy (ART). The second interest is development of adjuvant immune-based therapies (IBT) to improve immune restoration in CD4 lymphopenic conditions such as HIV and idiopathic CD4 lymphopenia (ICL). ICL is a rare, likely heterogeneous condition characterized by low CD4 T-cell counts in the absence of HIV or other known infection or disease that can cause lymphopenia.
Dr. Sereti received her M.D. from the University of Athens, Greece, in 1991. She did research for one year in Dr. Greg Spear’s laboratory at Rush Presbyterian Hospital in Chicago and then completed an internship, residency, and chief residency in medicine at Northwestern University. In 1997, Dr. Sereti came to the National Institutes of Health as a clinical associate in the Laboratory of Immunoregulation. She became a staff clinician in 2003. She was appointed to a clinical tenure-track position in 2009.
Virginia M. Sheikh
Amrit Pal Singh
William Lee Thompson
Puronen CE, Thompson WL, Imamichi H, Beq S, Hodge JN, Rehm C, Parker R, DerSimonian R, Brenchley JM, Sereti I. Decreased interleukin 7 responsiveness of T lymphocytes in patients with idiopathic CD4 lymphopenia. J Infect Dis. 2012 May;205(9):1382-90.
Mahnke YD, Greenwald JH, DerSimonian R, Roby G, Antonelli LR, Sher A, Roederer M, Sereti I. Selective expansion of polyfunctional pathogen-specific CD4(+) T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome. Blood. 2012 Mar 29;119(13):3105-12.
Boulware DR, Hullsiek KH, Puronen CE, Rupert A, Baker JV, French MA, Bohjanen PR, Novak RM, Neaton JD, Sereti I; INSIGHT Study Group. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis. 2011 Jun 1;203(11):1637-46.
Ciccone EJ, Greenwald JH, Lee PI, Biancotto A, Read SW, Yao MA, Hodge JN, Thompson WL, Kovacs SB, Chairez CL, Migueles SA, Kovacs JA, Margolis LB, Sereti I. CD4+ T cells, including Th17 and cycling subsets, are intact in the gut mucosa of HIV-1-infected long-term nonprogressors. J Virol. 2011 Jun;85(12):5880-8.
Musselwhite LW, Sheikh V, Norton TD, Rupert A, Porter BO, Penzak SR, Skinner J, Mican JM, Hadigan C, Sereti I. Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV. AIDS. 2011 Mar 27;25(6):787-95.
Parker R, Sereti I. The power of 1 in HIV therapeutics. Blood. 2011 Mar 10;117(10):2746-7.
Visit PubMed for a complete publication listing.
back to top
Immune Reconstitution Syndrome in HIV-Infected Patients Taking Antiretroviral Therapy, NCT00286767
Study on Interleukin-7 (CYT107) in HIV Patients (Inspire 2), NCT01190111
Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE), NCT00839436
Last Updated May 29, 2012
Last Reviewed May 29, 2012